CN103463531A - Use of rhizoma smilacis glabrae extract in preparation of lipid-lowering and fat-reducing medicines and health-care foods - Google Patents
Use of rhizoma smilacis glabrae extract in preparation of lipid-lowering and fat-reducing medicines and health-care foods Download PDFInfo
- Publication number
- CN103463531A CN103463531A CN2013104459182A CN201310445918A CN103463531A CN 103463531 A CN103463531 A CN 103463531A CN 2013104459182 A CN2013104459182 A CN 2013104459182A CN 201310445918 A CN201310445918 A CN 201310445918A CN 103463531 A CN103463531 A CN 103463531A
- Authority
- CN
- China
- Prior art keywords
- rhizoma smilacis
- smilacis glabrae
- ethanol
- extract
- fat
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003814 drug Substances 0.000 title claims abstract description 15
- 229940079593 drug Drugs 0.000 title claims abstract description 10
- 238000002360 preparation method Methods 0.000 title claims abstract description 10
- 235000013305 food Nutrition 0.000 title abstract description 10
- ZROGCCBNZBKLEL-FHXNIQKESA-N Astilbin Natural products O([C@H]1[C@@H](c2cc(O)c(O)cc2)Oc2c(c(O)cc(O)c2)C1=O)[C@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](C)O1 ZROGCCBNZBKLEL-FHXNIQKESA-N 0.000 claims abstract description 50
- ZROGCCBNZBKLEL-MPRHSVQHSA-N astilbin Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1O[C@H]1C(=O)C2=C(O)C=C(O)C=C2O[C@@H]1C1=CC=C(O)C(O)=C1 ZROGCCBNZBKLEL-MPRHSVQHSA-N 0.000 claims abstract description 46
- VQUPQWGKORWZII-UHFFFAOYSA-N Neoisoengelitin Natural products OC1C(O)C(O)C(C)OC1OC1C(=O)C2=C(O)C=C(O)C=C2OC1C1=CC=C(O)C=C1 VQUPQWGKORWZII-UHFFFAOYSA-N 0.000 claims abstract description 15
- CXQWRCVTCMQVQX-LSDHHAIUSA-N (+)-taxifolin Chemical compound C1([C@@H]2[C@H](C(C3=C(O)C=C(O)C=C3O2)=O)O)=CC=C(O)C(O)=C1 CXQWRCVTCMQVQX-LSDHHAIUSA-N 0.000 claims abstract description 14
- VQUPQWGKORWZII-WDPYGAQVSA-N (2r,3r)-5,7-dihydroxy-2-(4-hydroxyphenyl)-3-[(2s,3r,4r,5r,6s)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxy-2,3-dihydrochromen-4-one Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1O[C@H]1C(=O)C2=C(O)C=C(O)C=C2O[C@@H]1C1=CC=C(O)C=C1 VQUPQWGKORWZII-WDPYGAQVSA-N 0.000 claims abstract description 8
- QNVSXXGDAPORNA-UHFFFAOYSA-N Resveratrol Natural products OC1=CC=CC(C=CC=2C=C(O)C(O)=CC=2)=C1 QNVSXXGDAPORNA-UHFFFAOYSA-N 0.000 claims abstract description 8
- LUKBXSAWLPMMSZ-OWOJBTEDSA-N Trans-resveratrol Chemical compound C1=CC(O)=CC=C1\C=C\C1=CC(O)=CC(O)=C1 LUKBXSAWLPMMSZ-OWOJBTEDSA-N 0.000 claims abstract description 8
- 235000021283 resveratrol Nutrition 0.000 claims abstract description 8
- 229940016667 resveratrol Drugs 0.000 claims abstract description 8
- VQUPQWGKORWZII-RPJYBVRZSA-N Isoengeletin Chemical compound C[C@H]1[C@@H]([C@H]([C@H]([C@@H](O1)O[C@H]2[C@H](OC3=CC(=CC(=C3C2=O)O)O)C4=CC=C(C=C4)O)O)O)O VQUPQWGKORWZII-RPJYBVRZSA-N 0.000 claims abstract description 7
- KQNGHARGJDXHKF-UHFFFAOYSA-N dihydrotamarixetin Natural products C1=C(O)C(OC)=CC=C1C1C(O)C(=O)C2=C(O)C=C(O)C=C2O1 KQNGHARGJDXHKF-UHFFFAOYSA-N 0.000 claims abstract description 7
- ZROGCCBNZBKLEL-AEGLVIMLSA-N Isoastibin Natural products O([C@@H]1[C@H](c2cc(O)c(O)cc2)Oc2c(c(O)cc(O)c2)C1=O)[C@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](C)O1 ZROGCCBNZBKLEL-AEGLVIMLSA-N 0.000 claims abstract description 6
- ZROGCCBNZBKLEL-MFSALPCASA-N neoastilbin Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1O[C@@H]1C(=O)C2=C(O)C=C(O)C=C2O[C@H]1C1=CC=C(O)C(O)=C1 ZROGCCBNZBKLEL-MFSALPCASA-N 0.000 claims abstract description 6
- ZROGCCBNZBKLEL-RMPKKLJSSA-N neoastilbin Natural products C[C@@H]1O[C@H](O[C@H]2[C@@H](Oc3cc(O)cc(O)c3C2=O)c2ccc(O)c(O)c2)[C@H](O)[C@H](O)[C@H]1O ZROGCCBNZBKLEL-RMPKKLJSSA-N 0.000 claims abstract description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 56
- 239000011347 resin Substances 0.000 claims description 14
- 229920005989 resin Polymers 0.000 claims description 14
- 239000006228 supernatant Substances 0.000 claims description 14
- 235000013402 health food Nutrition 0.000 claims description 9
- 239000000463 material Substances 0.000 claims description 9
- 238000010521 absorption reaction Methods 0.000 claims description 7
- -1 acyl shikimic acid Chemical compound 0.000 claims description 7
- 230000037213 diet Effects 0.000 claims description 7
- 235000005911 diet Nutrition 0.000 claims description 7
- 239000003480 eluent Substances 0.000 claims description 7
- 238000010828 elution Methods 0.000 claims description 7
- JXOHGGNKMLTUBP-JKUQZMGJSA-N shikimic acid Natural products O[C@@H]1CC(C(O)=O)=C[C@H](O)[C@@H]1O JXOHGGNKMLTUBP-JKUQZMGJSA-N 0.000 claims description 7
- 238000002137 ultrasound extraction Methods 0.000 claims description 7
- 238000001291 vacuum drying Methods 0.000 claims description 7
- 230000009514 concussion Effects 0.000 claims description 5
- 239000002904 solvent Substances 0.000 claims description 5
- 238000000605 extraction Methods 0.000 claims description 4
- 230000006837 decompression Effects 0.000 claims description 2
- 238000001914 filtration Methods 0.000 claims description 2
- 238000011084 recovery Methods 0.000 claims description 2
- 238000004064 recycling Methods 0.000 claims description 2
- 241000699670 Mus sp. Species 0.000 abstract description 21
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 abstract description 18
- 210000002966 serum Anatomy 0.000 abstract description 11
- 230000037396 body weight Effects 0.000 abstract description 10
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 abstract description 10
- 235000012000 cholesterol Nutrition 0.000 abstract description 9
- 230000000694 effects Effects 0.000 abstract description 7
- 238000002474 experimental method Methods 0.000 abstract description 4
- 210000000683 abdominal cavity Anatomy 0.000 abstract description 3
- SHRMTKTUPUSTHH-UHFFFAOYSA-N 5-O-caffeoylshikimic acid Natural products OC1C=C(O)CC(OC(=O)C=Cc2ccc(O)c(O)c2)C1O SHRMTKTUPUSTHH-UHFFFAOYSA-N 0.000 abstract description 2
- QMPHZIPNNJOWQI-GDDAOPKQSA-N 5-[(E)-caffeoyl]shikimic acid Chemical compound O[C@@H]1[C@H](O)C=C(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 QMPHZIPNNJOWQI-GDDAOPKQSA-N 0.000 abstract description 2
- 241001465754 Metazoa Species 0.000 abstract description 2
- QMPHZIPNNJOWQI-UMVBOHGHSA-N NP-000588 Natural products O[C@@H]1C=C(C[C@@H](OC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)C(=O)O QMPHZIPNNJOWQI-UMVBOHGHSA-N 0.000 abstract description 2
- 229940126680 traditional chinese medicines Drugs 0.000 abstract 2
- VQUPQWGKORWZII-KTLFEHCLSA-N Dihydrokaempferol-3-O-alpha-L-rhamnopyranoside Natural products O([C@@H]1[C@H](c2ccc(O)cc2)Oc2c(c(O)cc(O)c2)C1=O)[C@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](C)O1 VQUPQWGKORWZII-KTLFEHCLSA-N 0.000 abstract 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 14
- 239000003651 drinking water Substances 0.000 description 10
- 235000020188 drinking water Nutrition 0.000 description 10
- 230000035611 feeding Effects 0.000 description 7
- 229930003944 flavone Natural products 0.000 description 6
- 235000011949 flavones Nutrition 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- 230000036541 health Effects 0.000 description 5
- 238000004128 high performance liquid chromatography Methods 0.000 description 5
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 description 4
- 150000002212 flavone derivatives Chemical class 0.000 description 4
- 150000002632 lipids Chemical class 0.000 description 4
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical group CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 241001619461 Poria <basidiomycete fungus> Species 0.000 description 3
- 239000002671 adjuvant Substances 0.000 description 3
- 210000003734 kidney Anatomy 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 210000000952 spleen Anatomy 0.000 description 3
- 208000024172 Cardiovascular disease Diseases 0.000 description 2
- 208000031226 Hyperlipidaemia Diseases 0.000 description 2
- 208000008589 Obesity Diseases 0.000 description 2
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 2
- 230000036528 appetite Effects 0.000 description 2
- 235000019789 appetite Nutrition 0.000 description 2
- 230000013872 defecation Effects 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 150000002213 flavones Chemical class 0.000 description 2
- 241000411851 herbal medicine Species 0.000 description 2
- 239000007791 liquid phase Substances 0.000 description 2
- 238000012423 maintenance Methods 0.000 description 2
- 235000020824 obesity Nutrition 0.000 description 2
- 150000007965 phenolic acids Chemical class 0.000 description 2
- 238000010298 pulverizing process Methods 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 238000004659 sterilization and disinfection Methods 0.000 description 2
- PJANXHGTPQOBST-UHFFFAOYSA-N stilbene Chemical class C=1C=CC=CC=1C=CC1=CC=CC=C1 PJANXHGTPQOBST-UHFFFAOYSA-N 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 230000002195 synergetic effect Effects 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- HVCOBJNICQPDBP-UHFFFAOYSA-N 3-[3-[3,5-dihydroxy-6-methyl-4-(3,4,5-trihydroxy-6-methyloxan-2-yl)oxyoxan-2-yl]oxydecanoyloxy]decanoic acid;hydrate Chemical compound O.OC1C(OC(CC(=O)OC(CCCCCCC)CC(O)=O)CCCCCCC)OC(C)C(O)C1OC1C(O)C(O)C(O)C(C)O1 HVCOBJNICQPDBP-UHFFFAOYSA-N 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- 208000031648 Body Weight Changes Diseases 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- 229930186217 Glycolipid Natural products 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 241000234280 Liliaceae Species 0.000 description 1
- 206010033307 Overweight Diseases 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 241001404789 Smilax glabra Species 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- PJANXHGTPQOBST-VAWYXSNFSA-N Stilbene Natural products C=1C=CC=CC=1/C=C/C1=CC=CC=C1 PJANXHGTPQOBST-VAWYXSNFSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 241000282894 Sus scrofa domesticus Species 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 230000003143 atherosclerotic effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 238000010241 blood sampling Methods 0.000 description 1
- 210000000476 body water Anatomy 0.000 description 1
- 230000004579 body weight change Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 235000009569 green tea Nutrition 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 235000009048 phenolic acids Nutrition 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- JXOHGGNKMLTUBP-HSUXUTPPSA-N shikimic acid Chemical compound O[C@@H]1CC(C(O)=O)=C[C@@H](O)[C@H]1O JXOHGGNKMLTUBP-HSUXUTPPSA-N 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 235000021286 stilbenes Nutrition 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 239000013585 weight reducing agent Substances 0.000 description 1
Images
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention belongs to the field of traditional Chinese medicines and relates to a use of rhizoma smilacis glabrae extract in preparation of lipid-lowering and fat-reducing medicines and health-care foods. The rhizoma smilacis glabrae extract comprises 5-O-caffeoylshikimic acid, astilbin, isoastilbin, neoastilbin, neoisoastilbin, taxifolin, engeletin, isoengelitin and resveratrol. An animal experiment shows that the rhizoma smilacis glabrae extract can obviously reduce mice abdominal cavity fat weight, reduce mice body weight, and reduce triglyceride and total cholesterol concentrations of mice serum. Effects of the rhizoma smilacis glabrae extract are stronger than effects of a single astilbin component. The rhizoma smilacis glabrae extract is extracted from traditional Chinese medicines, has synergism of components, has good fat-reducing effects and broadens a rhizoma smilacis glabrae application range.
Description
Technical field
The invention belongs to drug world, relate in particular to the application of a kind of Chinese medicine extract in lipid-lowering diet drug and health food.
Background technology
Along with the raising of living standards of the people, the problem such as the obesity caused because of energy Excessive Intake (high fat, high-carbohydrate diet), hyperlipidemia is day by day serious.Obesity not only affects the bodily form, the more important thing is it and diabetes, the morbidity positive correlation of the diseases such as hypertension.Hyperlipidemia is to cause atherosclerotic principal element, and then may cause the multiple cardiovascular and cerebrovascular diseases such as thrombosis and myocardial infarction.During survey data shows, state-owned 11% child and 30% adult are overweight, and at least there is a kind of glycolipid metabolism Indexes Abnormality in 42% child, China facing cardiovascular disease incidence rate sharp increase risk.Therefore, research and develop medicine or the health food of lowering blood-fat and reducing weight safely and effectively and there is very important social meaning.
Rhizoma Smilacis Glabrae is the rhizome of Liliaceae smilax plant smilacis glabra (Smilax glabra Roxb.), is the conventional Chinese medicine that Chinese Pharmacopoeia is included, and is also that Ministry of Public Health allows one of Chinese herbal medicine used in health food.Chemical constitution study shows that Rhizoma Smilacis Glabrae mainly contains the flavonoid substances such as astilbin, engelitin; In addition, it also contains stilbene class and the phenolic acids such as resveratrol, shikimic acid, 5-O-caffeoyl shikimic acid.But the research report that Rhizoma Smilacis Glabrae extract lowering blood-fat and reducing weight aspect is not yet arranged at present.We study and find that Rhizoma Smilacis Glabrae extract can significantly reduce the mouse peritoneal fat weight, alleviate Mouse Weight, reduce triglyceride and total cholesterol concentration in mice serum simultaneously, there is good functions of lowering blood-fat and reducing weight, aspect blood fat reducing and slimming medicine and health food, there is important using value.
Summary of the invention
The object of the invention is to provide the application of Rhizoma Smilacis Glabrae extract in preparation lipid-lowering diet drug and health food.
Specifically comprise following technical scheme:
The application of Rhizoma Smilacis Glabrae extract in preparation lipid-lowering diet drug and health food.
Comprise 5-O-coffee acyl shikimic acid, astilbin, isoastilbin, neoastilbin, neoisoastilbin, Taxifolin, engelitin, isoengelitin, resveratrol in described Rhizoma Smilacis Glabrae extract;
Described Rhizoma Smilacis Glabrae extract extraction step comprises: rhizoma smilacis glabrae medicinal material is pulverized, ethanol ultrasonic extraction, decompression recycling ethanol, centrifugal rear acquisition supernatant; Add beta-schardinger dextrin--starch-resin in supernatant, shake the rear filtration of absorption, ethanol elution twice for resin, collect eluent, and 40 ~ 50 ℃ of vacuum dryings after recovery ethanol, obtain Rhizoma Smilacis Glabrae extract.
Extraction step is preferably: rhizoma smilacis glabrae medicinal material was pulverized 40 mesh sieves, and with 10 times of volume 60% ethanol ultrasonic extraction, 60 ℃ of reclaim under reduced pressure are extracted ethanol in solvent, centrifugal rear acquisition supernatant; 40-60 order beta-schardinger dextrin--starch-resin toward adding in supernatant with the weight such as rhizoma smilacis glabrae medicinal material, filter after concussion absorption 30 min, and 60% ethanol elution twice resin for, collect eluent, reclaims 40 ~ 50 ℃ of vacuum dryings after ethanol, the acquisition Rhizoma Smilacis Glabrae extract.
This lipid-lowering diet drug also comprises pharmaceutically acceptable adjuvant, as starch, cyclodextrin etc.Can need to add adjuvant commonly used according to dosage form.
These lowering blood-fat and reducing weight health product can need to add adjuvant commonly used according to the preparation of health product, make various dosage forms.This is routine techniques, repeats no more.
The invention has the beneficial effects as follows: (1) raw material adopts the natural Chinese medicine raw material, safer.(2) weight reduction with drugs that prepared by this Rhizoma Smilacis Glabrae extract is effective, has expanded the purposes of Rhizoma Smilacis Glabrae.(3) astilbin shows to have functions of lowering blood-fat and reducing weight through zoopery, result also shows that the Rhizoma Smilacis Glabrae extract functions of lowering blood-fat and reducing weight is stronger simultaneously, show that other compositions in astilbin and Rhizoma Smilacis Glabrae extract have synergistic function on lowering blood-fat and reducing weight, have beyond thought effect.
Below by experiment and the result of Rhizoma Smilacis Glabrae extract lowering blood-fat and reducing weight, further illustrate essence of the present invention for better illustrating.
Rhizoma Smilacis Glabrae extract: Rhizoma Smilacis Glabrae was pulverized 40 mesh sieves, with 10 times of volume 60% ethanol ultrasonic extraction, 60
othe C reclaim under reduced pressure is extracted ethanol in solvent, centrifugal rear acquisition supernatant.40-60 order beta-schardinger dextrin--starch-resin toward adding in supernatant with the weight such as rhizoma smilacis glabrae medicinal material, filter after concussion absorption 30 min, and 60% ethanol elution twice resin for, collect eluent, reclaims 40 ~ 50 ℃ of vacuum dryings after ethanol, the acquisition Rhizoma Smilacis Glabrae extract.
The high-efficient liquid phase chromatogram that Fig. 1 is this Rhizoma Smilacis Glabrae extract (HPLC).HPLC system used is Waters 600, is equipped with dual wavelength detector and online degas system.Chromatographic column is Agilent Zorbax SB C18 post (250 mm * 4.6 mm i.d., 5 μ m).Mobile phase is acetonitrile (A) and 0.1% aqueous acetic acid (B).The linear gradient program is 0 – 15min, 16 – 21% A; 15 – 40 min, 21 – 40% A.Flow velocity is 1 mL/min.Sample size is 10 μ L, and detecting wavelength is 291 nm.In figure, peak 1 is 5-O-coffee acyl shikimic acid; peak 3 is astilbin; peak 2,5,6 is astilbin isomer (isoastilbin, neoastilbin, neoisoastilbin); peak 4 is Taxifolin; peak 7,8 is engelitin and isoengelitin; peak 9 is resveratrol, and each molecular structure of compounds is shown in Fig. 2.Peak 2,3,4,5,6,7,8 is chromocor compound, by they peak area sum substitution astilbin standard curves, calculates general flavone content in extract (in astilbin).Analysis result shows that in extract, the astilbin proportion is very large, is about 50%.
Its lowering blood-fat and reducing weight effect experiment is as follows:
Astilbin: purity > 98%, purchased from Shanghai Tongtian Biotechnology Co., Ltd..
Fetch earth 1 part of Poria extract, add two parts of beta-schardinger dextrin-s, mixes its water solublity of rear raising.Get 1 part of astilbin, add two parts of beta-schardinger dextrin-s, mix.
70 4 week age female ICR mice be divided at random 7 groups (I, II, III, IV, V, VI and VII groups), 10 every group.Wherein, the I group is basic matched group, the feeding normal feedstuff; The II group is high fat matched group, the feeding high lipid food; III, IV and V feeding high lipid food, and add Rhizoma Smilacis Glabrae extract in drinking water, in total flavones wherein, total flavones concentration is respectively 1 mg/ml(III group), 2 mg/ml(IV groups) and 4 mg/ml(V groups); VI and VII group feeding high lipid food, and add astilbin in drinking water, concentration is respectively 1 mg/ml(VI group), 2 mg/ml(VII groups).Described high lipid food consists of 85% normal feedstuff+10% Adeps Sus domestica+5% sucrose.All mice free choice feedings and drinking-water, raise 8 weeks, weighs weekly.After experiment finishes, from the heart blood sampling, separation of serum, analyze triglyceride and cholesterol concentration in mice serum; Dissecting animal gathers in mouse peritoneal the tissue such as fatty tissue, spleen, kidney, liver and weighs.
Table one is different disposal group Mouse Weight and feeding time relation.By table one, known, the increase of high fat control group mice body weight is significantly faster than the normal feedstuff matched group, and body weight difference has statistical significance (p<0.05).Compare with high fat matched group, add Rhizoma Smilacis Glabrae extract and can significantly reduce the Mouse Weight increase in drinking water, body weight difference has statistical significance (p<0.05), and concentration is higher, and effect is more remarkable.Compare with high fat matched group, add astilbin and also can reduce Mouse Weight, but body weight difference not statistically significant (p > 0.05).Table two is different disposal group mice at average food ration and the amount of drinking water of the 3rd week and the 7th week.As shown in Table 2, with high fat matched group, compare, add food ration and amount of drinking water that Rhizoma Smilacis Glabrae extract or astilbin can not reduce mice in drinking water, illustrate that respectively organizing Mouse Weight increase difference is not caused by food ration.
Mice is got abdominal cavity fat, liver, kidney and spleen and weighs after dissecting, and statistical result is in Table three.Experimental result shows, with the normal feedstuff group, compares, and high fat control group mice abdominal cavity fat weight significantly increases (p<0.05).Compare with high fat matched group, add Rhizoma Smilacis Glabrae extract and can significantly reduce mouse peritoneal fat weight (p<0.05) in drinking water.Compare with high fat matched group, add astilbin and also can reduce the mouse peritoneal fat weight, but the difference not statistically significant (p > 0.05).Liver, kidney and spleen weighing results show between each group without significant difference, illustrate that Rhizoma Smilacis Glabrae extract and astilbin are all dirty without impact on the mice device, do not affect mice health.
Triglyceride in serum and T-CHOL index determining result show (table four), compare high fat control group mice triglyceride in serum and total cholesterol concentration significantly raise (p<0.05) with the normal feedstuff group.Compare with high fat matched group, add Rhizoma Smilacis Glabrae extract and can significantly reduce triglyceride and total cholesterol concentration (p<0.05) in mice serum in drinking water.Compare with high fat matched group, add astilbin and also can reduce triglyceride and total cholesterol concentration in mice serum, but the difference not statistically significant (p > 0.05).
Above experimental result shows, Rhizoma Smilacis Glabrae extract can significantly reduce the mouse peritoneal fat weight, alleviates Mouse Weight, reduces triglyceride and total cholesterol concentration in mice serum simultaneously, and difference has statistical significance (p<0.05).And the astilbin one-component, although also can alleviate Mouse Weight, reduces triglyceride and total cholesterol concentration in mice serum, difference is (p > 0.05) not significantly.
The HPLC analysis result shows in Rhizoma Smilacis Glabrae extract; except mainly containing astilbin; also contain the flavone components such as astilbin isomer, Taxifolin, engelitin and isoengelitin, also contain in addition phenolic acid and the stilbene constituents such as 5-O-coffee acyl shikimic acid, resveratrol.In these compositions, astilbin shows to have functions of lowering blood-fat and reducing weight through zoopery, result also shows that the Rhizoma Smilacis Glabrae extract functions of lowering blood-fat and reducing weight is stronger simultaneously, show that other compositions in astilbin and Rhizoma Smilacis Glabrae extract have synergistic function on lowering blood-fat and reducing weight, give Rhizoma Smilacis Glabrae extract better functions of lowering blood-fat and reducing weight, effect is better than wherein main component astilbin one-component.Rhizoma Smilacis Glabrae is that health ministry allows one of Chinese herbal medicine used in health food, so Rhizoma Smilacis Glabrae extract has broad application prospects at lowering blood-fat and reducing weight health product and pharmaceutical preparations.
The different feeding time Mouse Weight of table one table (meansigma methods ± SE, n=10)
I group is basic matched group, and the II group is high fat matched group, and III, IV and V add respectively Rhizoma Smilacis Glabrae extract 1 mg/ml(III), 2 mg/ml(IV) and 4 mg/ml(V); VI and VII group are added respectively astilbin 1 mg/ml(VI) and 2 mg/ml(VII).
acompare with basic matched group that there were significant differences (p<0.05);
bcompare with high fat matched group that there were significant differences (p<0.05).
The average food ration of table two mice and amount of drinking water (meansigma methods ± SD, n=7)
I group is basic matched group, and the II group is high fat matched group, and III, IV and V add respectively Rhizoma Smilacis Glabrae extract 1 mg/ml(III), 2 mg/ml(IV) and 4 mg/ml(V); VI and VII group are added respectively astilbin 1 mg/ml(VI) and 2 mg/ml(VII).
acompare with basic matched group that there were significant differences (p<0.05);
bcompare with high fat matched group that there were significant differences (p<0.05).
The dirty index of table three mouse peritoneal fat and device (meansigma methods ± SE, n=10)
I group is basic matched group, and the II group is high fat matched group, and III, IV and V add respectively Rhizoma Smilacis Glabrae extract 1 mg/ml(III), 2 mg/ml(IV) and 4 mg/ml(V); VI and VII group are added respectively astilbin 1 mg/ml(VI) and 2 mg/ml(VII).
acompare with basic matched group that there were significant differences (p<0.05);
bcompare with high fat matched group that there were significant differences (p<0.05).
Triglyceride and total cholesterol concentration (meansigma methods ± SE, n=10) in table four mice serum
I group is basic matched group, and the II group is high fat matched group, and III, IV and V add respectively Rhizoma Smilacis Glabrae extract 1 mg/ml(III), 2 mg/ml(IV) and 4 mg/ml(V); VI and VII group are added respectively astilbin 1 mg/ml(VI) and 2 mg/ml(VII).
acompare with basic matched group that there were significant differences (p<0.05);
bcompare with high fat matched group that there were significant differences (p<0.05).
The accompanying drawing explanation
Fig. 1 Rhizoma Smilacis Glabrae extract high-efficient liquid phase chromatogram
Each chromatographic peak molecular structure in Fig. 2 Rhizoma Smilacis Glabrae extract.
The specific embodiment
Below in conjunction with specific embodiment, the present invention will be further described, but the invention is not restricted to these embodiment.
Rhizoma Smilacis Glabrae lowering blood-fat and reducing weight capsule, preparation as follows:
(1) Rhizoma Smilacis Glabrae extract: Rhizoma Smilacis Glabrae was pulverized 40 mesh sieves, with 10 times of volume 60% ethanol ultrasonic extraction, 60
othe C reclaim under reduced pressure is extracted ethanol in solvent, centrifugal rear acquisition supernatant.40-60 order beta-schardinger dextrin--starch-resin toward adding in supernatant with the weight such as rhizoma smilacis glabrae medicinal material, filter after concussion absorption 30 min, and 60% ethanol elution twice resin for, collect eluent, reclaims 40 ~ 50 ℃ of vacuum dryings after ethanol, the acquisition Rhizoma Smilacis Glabrae extract.
(2) detect through high performance liquid chromatography, contain 5-O-coffee acyl shikimic acid, astilbin, isoastilbin, neoastilbin, neoisoastilbin, Taxifolin, engelitin, isoengelitin, resveratrol.General flavone content in extract (take astilbin) is 76.6%.
(3) Poria extract 500 grams that fetch earth, cross 60 mesh sieves after pulverizing; Separately get beta-schardinger dextrin-2000g, mix.
(4) after sterilization treatment, in humidity, be pelletize under the 20-40% environment, granularity is between 20 ~ 40 orders.
(5) in humidity, be 50% encapsulated in interior environment, every heavily about 0.5 g.
Rhizoma Smilacis Glabrae lowering blood-fat and reducing weight electuary, preparation by the following method:
(1) Rhizoma Smilacis Glabrae extract: Rhizoma Smilacis Glabrae was pulverized 40 mesh sieves, with 10 times of volume 60% ethanol ultrasonic extraction, 60
othe C reclaim under reduced pressure is extracted ethanol in solvent, centrifugal rear acquisition supernatant.40-60 order beta-schardinger dextrin--starch-resin toward adding in supernatant with the weight such as rhizoma smilacis glabrae medicinal material, filter after concussion absorption 30 min, and 60% ethanol elution twice resin for, collect eluent, reclaims 40 ~ 50 ℃ of vacuum dryings after ethanol, the acquisition Rhizoma Smilacis Glabrae extract.
(2) detect through high performance liquid chromatography, contain 5-O-coffee acyl shikimic acid, astilbin, isoastilbin, neoastilbin, neoisoastilbin, Taxifolin, engelitin, isoengelitin, resveratrol.General flavone content in extract (take astilbin) is 76.6%.
(3) Poria extract 500 grams that fetch earth, cross 60 mesh sieves after pulverizing; Separately get beta-schardinger dextrin-2000g, instant green tea powder 500 grams, aspartame 40 grams, mix.
(4) after sterilization treatment, in humidity, be pelletize under the 20-40% environment, granularity is between 20 ~ 40 orders.
(5) in humidity, be 50% to pack in interior environment, every bag heavy 3.6 g.
The functional observation of the lowering blood-fat and reducing weight electuary of preparation
Get embodiment 2 lowering blood-fat and reducing weight electuaries on probation through 8 volunteers, 6 female 2 men, body weight is 60-80kg.Two bags of every days, 15 days on probation, during the situations such as inquiry volunteer appetite, spirit, sleep, defecation, record volunteer's body weight change situation.8 volunteers all feed back the trial employment period does not affect appetite, spirit, sleep, defecation etc., the weighing body weight result all reflection effectively, the scope of losing weight is 0.5-2 kg.Exemplary:
Yuan *, the female, 30 years old, front body weight on probation was 65.4 kg, tried out body weight after 15 days and was kept to 64.2 kg; Rear drug withdrawal 10 days, weight maintenance is 64.2 kg; Take electuary 15 days, body weight reduces to 63.2 kg again, and after drug withdrawal, weight maintenance does not rebound.
Claims (4)
1. the application of Rhizoma Smilacis Glabrae extract in preparation lipid-lowering diet drug and health food.
2. application as claimed in claim 1, is characterized in that containing 5-O-coffee acyl shikimic acid, astilbin, isoastilbin, neoastilbin, neoisoastilbin, Taxifolin, engelitin, isoengelitin, resveratrol.
3. application as claimed in claim 1 is characterized in that described Rhizoma Smilacis Glabrae extract extraction step comprises: rhizoma smilacis glabrae medicinal material is pulverized, ethanol ultrasonic extraction, decompression recycling ethanol, centrifugal rear acquisition supernatant; Add beta-schardinger dextrin--starch-resin in supernatant, shake the rear filtration of absorption, ethanol elution twice for resin, collect eluent, and 40 ~ 50 ℃ of vacuum dryings after recovery ethanol, obtain Rhizoma Smilacis Glabrae extract.
4. application as claimed in claim 3 is characterized in that described extraction step: rhizoma smilacis glabrae medicinal material was pulverized 40 mesh sieves, and with 10 times of volume 60% ethanol ultrasonic extraction, 60 ℃ of reclaim under reduced pressure are extracted ethanol in solvent, centrifugal rear acquisition supernatant; 40-60 order beta-schardinger dextrin--starch-resin toward adding in supernatant with the weight such as rhizoma smilacis glabrae medicinal material, filter after concussion absorption 30 min, and 60% ethanol elution twice resin for, collect eluent, reclaims 40 ~ 50 ℃ of vacuum dryings after ethanol, the acquisition Rhizoma Smilacis Glabrae extract.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310445918.2A CN103463531B (en) | 2013-09-27 | 2013-09-27 | Use of rhizoma smilacis glabrae extract in preparation of lipid-lowering and fat-reducing medicines and health-care foods |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310445918.2A CN103463531B (en) | 2013-09-27 | 2013-09-27 | Use of rhizoma smilacis glabrae extract in preparation of lipid-lowering and fat-reducing medicines and health-care foods |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN103463531A true CN103463531A (en) | 2013-12-25 |
| CN103463531B CN103463531B (en) | 2015-03-11 |
Family
ID=49788723
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201310445918.2A Active CN103463531B (en) | 2013-09-27 | 2013-09-27 | Use of rhizoma smilacis glabrae extract in preparation of lipid-lowering and fat-reducing medicines and health-care foods |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103463531B (en) |
Cited By (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103961603A (en) * | 2014-03-14 | 2014-08-06 | 广西正堂药业有限责任公司 | Traditional Chinese medicine preparationcapable of reducing blood fat and freeing vessels |
| CN106138127A (en) * | 2016-08-15 | 2016-11-23 | 锦州医科大学 | There is gland calyx Herba astilbes chinensis extract and the application thereof improving and preventing and treating obesity effect |
| CN106492069A (en) * | 2016-12-09 | 2017-03-15 | 南方医科大学南方医院 | Prevent and treat effective ingredient in Chinese of chronic pelvic inflammatory disease and its preparation method and application |
| CN106974287A (en) * | 2017-05-08 | 2017-07-25 | 中山森谱生物科技有限公司 | A kind of functional food containing Rhizoma Smilacis Glabrae extract and preparation method thereof |
| CN108373489A (en) * | 2018-03-16 | 2018-08-07 | 成都格利普生物科技有限公司 | The isolation and purification method of Astilbe chinensis glycoside isomers in smilax |
| CN108404004A (en) * | 2018-04-17 | 2018-08-17 | 江西中医药大学 | A kind of Rhizoma Smilacis Glabrae extract and its preparation method and application |
| CN108675978A (en) * | 2018-05-28 | 2018-10-19 | 江西农业大学 | A method of preparing high-purity texifolin by raw material of smilax |
| CN112641894A (en) * | 2020-01-19 | 2021-04-13 | 北京中医药大学 | A new Chinese medicinal composition for regulating lipid metabolism and improving gastrointestinal dysfunction |
| CN114452261A (en) * | 2021-12-31 | 2022-05-10 | 湖南茯神科技有限公司 | Preparation method and application of rhizoma smilacis glabrae alcohol extract oral tablet |
| WO2023065376A1 (en) * | 2021-10-19 | 2023-04-27 | 广州白云山敬修堂药业股份有限公司 | Use of composition comprising astilbin and/or isomer thereof in preparation of drug for treating psoriasis |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1381263A (en) * | 2002-05-16 | 2002-11-27 | 鲁京硕 | Weight-lossing hypolipemic medicine |
| CN102068589A (en) * | 2009-11-25 | 2011-05-25 | 冯科 | Blood fat reducing and weight losing medicinal composition and preparation method thereof |
-
2013
- 2013-09-27 CN CN201310445918.2A patent/CN103463531B/en active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1381263A (en) * | 2002-05-16 | 2002-11-27 | 鲁京硕 | Weight-lossing hypolipemic medicine |
| CN102068589A (en) * | 2009-11-25 | 2011-05-25 | 冯科 | Blood fat reducing and weight losing medicinal composition and preparation method thereof |
Non-Patent Citations (2)
| Title |
|---|
| 吴占全: "土茯苓的化学与药理研究进展", 《中国民族医药杂志》 * |
| 马跃平等: "土茯苓化学成分的分离与鉴定", 《沈阳药科大学学报》 * |
Cited By (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103961603B (en) * | 2014-03-14 | 2017-04-19 | 广西正堂药业有限责任公司 | Traditional Chinese medicine preparationcapable of reducing blood fat and freeing vessels |
| CN103961603A (en) * | 2014-03-14 | 2014-08-06 | 广西正堂药业有限责任公司 | Traditional Chinese medicine preparationcapable of reducing blood fat and freeing vessels |
| CN106138127A (en) * | 2016-08-15 | 2016-11-23 | 锦州医科大学 | There is gland calyx Herba astilbes chinensis extract and the application thereof improving and preventing and treating obesity effect |
| CN106492069B (en) * | 2016-12-09 | 2019-10-11 | 南方医科大学南方医院 | Chinese medicine composition and the application for preventing and treating chronic pelvic inflammatory disease |
| CN106492069A (en) * | 2016-12-09 | 2017-03-15 | 南方医科大学南方医院 | Prevent and treat effective ingredient in Chinese of chronic pelvic inflammatory disease and its preparation method and application |
| CN106974287A (en) * | 2017-05-08 | 2017-07-25 | 中山森谱生物科技有限公司 | A kind of functional food containing Rhizoma Smilacis Glabrae extract and preparation method thereof |
| CN108373489A (en) * | 2018-03-16 | 2018-08-07 | 成都格利普生物科技有限公司 | The isolation and purification method of Astilbe chinensis glycoside isomers in smilax |
| CN108404004A (en) * | 2018-04-17 | 2018-08-17 | 江西中医药大学 | A kind of Rhizoma Smilacis Glabrae extract and its preparation method and application |
| CN108675978A (en) * | 2018-05-28 | 2018-10-19 | 江西农业大学 | A method of preparing high-purity texifolin by raw material of smilax |
| CN108675978B (en) * | 2018-05-28 | 2021-06-01 | 江西农业大学 | Method for preparing high-purity taxifolin by taking rhizoma smilacis glabrae as raw material |
| CN112641894A (en) * | 2020-01-19 | 2021-04-13 | 北京中医药大学 | A new Chinese medicinal composition for regulating lipid metabolism and improving gastrointestinal dysfunction |
| CN112641894B (en) * | 2020-01-19 | 2022-06-17 | 北京中医药大学 | A new Chinese medicinal composition for regulating lipid metabolism and improving gastrointestinal dysfunction |
| WO2023065376A1 (en) * | 2021-10-19 | 2023-04-27 | 广州白云山敬修堂药业股份有限公司 | Use of composition comprising astilbin and/or isomer thereof in preparation of drug for treating psoriasis |
| CN114452261A (en) * | 2021-12-31 | 2022-05-10 | 湖南茯神科技有限公司 | Preparation method and application of rhizoma smilacis glabrae alcohol extract oral tablet |
Also Published As
| Publication number | Publication date |
|---|---|
| CN103463531B (en) | 2015-03-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103463531B (en) | Use of rhizoma smilacis glabrae extract in preparation of lipid-lowering and fat-reducing medicines and health-care foods | |
| CN101062077B (en) | Method for preparing stevia whole stevioside and stevia whole flavone at the same time | |
| Li et al. | Antinociceptive and anti-inflammatory activities of iridoid glycosides extract of Lamiophlomis rotata (Benth.) Kudo | |
| CN102058632B (en) | Application of medicinal composition to preparation of medicament for preventing and treating alcoholic liver damage and fatty liver and lowering blood fat | |
| CN103006878B (en) | A kind of fresh rehmannia root total glycosides extractive and preparation method and application | |
| CN103169788B (en) | Chinese date leaf extractive and application thereof in preparation of medicament or health food for preventing and treating liver injury | |
| CN104971090A (en) | Application of cyclocarya paliurus effective part in preparation of medicine used for treating non-alcoholic fatty liver disease | |
| CN102512482A (en) | Euonymus alatus extract, blood-sugar-reducing activity thereof and application of euonymus alatus extract to preparation of products for reducing blood sugar | |
| CN102743401A (en) | Application of panaxadiol saponins fraction in preparing medicine for preventing epilepsia | |
| CN101810686A (en) | Compatible composition for treating rheumatoid arthritis and preparation method thereof | |
| CN101972385A (en) | Method for preparing general flavone in star-of-Bethlehem and application thereof to antitumor, anti-inflammatory and analgesic medicines | |
| CN103721148B (en) | A kind of Fructus Alpiniae Oxyphyllae compositions treating acute/chronic gastroenteritis and preparation method thereof | |
| EP3403664B1 (en) | Use of cistanche tubulosa | |
| CN104982597A (en) | Multi-functional composite instant tea, as well as preparation method and use thereof | |
| CN101505779A (en) | A hypolipidemic composition and its use | |
| CN102875615A (en) | Extraction method and application of falcate dolichos root or leaf glucoside A and total saponins of falcate dolichos root or leaf | |
| CN102898322B (en) | Compound and preparation method and application thereof | |
| JP2011184305A (en) | Adiponectin production promoter | |
| Lan et al. | Safety assessment of saponins extract in Dolichos falcatus Klein: subchronic study in Sprague-Dawley rats | |
| CN100431566C (en) | Chinese medicine composition and its prepn process and application | |
| CN102861278B (en) | Lipid-lowering extract from effective parts of sharpleaf galangal fruit and preparation and application thereof | |
| CN103372040B (en) | Monas cuspurpureus Went Rhizoma Chuanxiong drug regimen of a kind of adjusting blood lipid and preparation method thereof | |
| CN115141288B (en) | Rhizoma anemarrhenae active polysaccharide, rhizoma anemarrhenae crude polysaccharide, and preparation method and application thereof | |
| CN101721493B (en) | Fat-reducing medicine and preparation method and application thereof | |
| CN101244220A (en) | Total saponins extract of Smilax scobinicaulis and its preparation method |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| TR01 | Transfer of patent right | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20181213 Address after: 331500 North Industrial Park of Yongfeng County, Ji'an City, Jiangxi Province Patentee after: The strong high-tech of Jiangxi Wei Laiying Co., Ltd Address before: 330045 Zhimin Avenue, Changbei Economic Development Zone, Nanchang City, Jiangxi Province Patentee before: Zhang Qingfeng |